iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline [Yahoo! Finance]
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
iBio, Inc. (NYSE: IBIO) was upgraded by analysts at StockNews.com to a "sell" rating.
iBio to Begin Trading on the Nasdaq Stock Exchange
iBio Reports Fiscal Second Quarter 2025 Financial Results [Yahoo! Finance]